SCH772984ERK1 and ERK2 inhibitor CAS# 942183-80-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 942183-80-4 | SDF | Download SDF |
PubChem ID | 24866313 | Appearance | Powder |
Formula | C33H33N9O2 | M.Wt | 587.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 14.29 mg/mL (24.32 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | (3R)-1-[2-oxo-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-N-(3-pyridin-4-yl-1H-indazol-5-yl)pyrrolidine-3-carboxamide | ||
SMILES | C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7 | ||
Standard InChIKey | HDAJDNHIBCDLQF-RUZDIDTESA-N | ||
Standard InChI | InChI=1S/C33H33N9O2/c43-30(42-18-16-41(17-19-42)27-5-2-24(3-6-27)32-35-11-1-12-36-32)22-40-15-10-25(21-40)33(44)37-26-4-7-29-28(20-26)31(39-38-29)23-8-13-34-14-9-23/h1-9,11-14,20,25H,10,15-19,21-22H2,(H,37,44)(H,38,39)/t25-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM, respectively. | |||||
Targets | ERK1 | ERK2 | ||||
IC50 | 4 nM | 1 nM |
Cell experiment [1]: | |
Cell lines | melanoma cell lines (M408, M202, WM1366) |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reacting condition | 24 h; 500 nM |
Applications | Treatment with SCH772984 for the sensitive M408 resulted in decreased pRSK, disappearance of pERK1/2, and slight induction of pMEK, with no change in total RSK, MEK, ERK 1/2, or AKT. For the resistant M202, a modest induction of pMEK with some decrease in pERK and pRSK was observed at 24 hours. Treatment with SCH772984 resulted in upregulation of pAKT levels for M408 and WM1366. |
Animal experiment [2]: | |
Animal models | Nude mice |
Dosage form | 25 mg/kg; b.i.d; intraperitoneal injection |
Application | The therapeutic effects of combining the CDK inhibitor Dinaciclib with inhibitors of ERK inhibitor SCH772984 were evaluated using two orthotopic patient-derived human pancreatic cancer xenograft models (Panc253 and Panc265). These models closely resemble the physiological and pathological conditions of pancreatic cancer in humans. A 2-3 mm3 tumor explant was implanted into the pancreas of nude mice and ultrasound imaging was used to measure the tumor size (3D) before randomization and treatment, which began when tumors grew to 50-100 mm3. The combination of Dinaciclib (20 mg/kg, i.p., t.i.w.) and SCH772984 (25 mg/kg, i.p., b.i.d.) dramatically inhibited the growth of primary orthotopic Panc265 (82.5%, p < 0.001) and Panc253 (95.7%, p <0.001) versus control, and also the number of metastatic lesions of both Panc265 (94.9%, p <0.001) and Panc253 (92.4%, p <0.02). |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Wong D J L, Robert L, Atefi M S, et al. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma[J]. Molecular cancer, 2014, 13(1): 194. [2] Hu C, Dadon T, Chenna V, et al. Abstract B263: Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) or ERK (SCH772984) dramatically blocks pancreatic tumor growth and metastases in patient-derived orthotopic xenograft models[J]. Molecular Cancer Therapeutics, 2013, 12(11 Supplement): B263-B263. |
SCH772984 Dilution Calculator
SCH772984 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7016 mL | 8.5082 mL | 17.0164 mL | 34.0327 mL | 42.5409 mL |
5 mM | 0.3403 mL | 1.7016 mL | 3.4033 mL | 6.8065 mL | 8.5082 mL |
10 mM | 0.1702 mL | 0.8508 mL | 1.7016 mL | 3.4033 mL | 4.2541 mL |
50 mM | 0.034 mL | 0.1702 mL | 0.3403 mL | 0.6807 mL | 0.8508 mL |
100 mM | 0.017 mL | 0.0851 mL | 0.1702 mL | 0.3403 mL | 0.4254 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SCH772984, identified by an affinity-based mass spectroscopy high-throughput platform, is a novel, potent and ATP-competitive inhibition of ERK1 and ERK2 with 50% inhibition concentration IC50 values of 4 nmol/L and 1 nmol/L respectively. Although it displays behaviors of both type I and type II kinase inhibitors, SCH772984 is highly selective against only seven kinases, including CLK2, FLT4, GSG2, MAP4K4, MAPK1, MINK1, PRKD1 and TTK, out of a wide range of 300 tested with more than 50% inhibition at a concentration of 1 μmol/L. Study results have shown that SCH772984 potently inhibits tumor cells with mutations in BRAF, NRAS and KRAS at nanomolar concentrations.
Reference
Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-750
- VTP-27999
Catalog No.:BCC2048
CAS No.:942142-51-0
- Methyl 3-indolecarboxylate
Catalog No.:BCN4487
CAS No.:942-24-5
- 8beta-(4'-Hydroxytigloyloxy)costunolide
Catalog No.:BCN7885
CAS No.:94190-32-6
- S-Ruxolitinib (INCB018424)
Catalog No.:BCC2201
CAS No.:941685-37-6
- INCB032304
Catalog No.:BCC6455
CAS No.:941685-27-4
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
- Selaginellin
Catalog No.:BCN8215
CAS No.:941269-84-7
- 1,3,5-Cadinatriene-3,8-diol
Catalog No.:BCN4486
CAS No.:941227-27-6
- 1'-Acetonaphthone
Catalog No.:BCC8446
CAS No.:941-98-0
- KD 5170
Catalog No.:BCC2420
CAS No.:940943-37-3
- SB743921
Catalog No.:BCC4559
CAS No.:940929-33-9
- R-7128
Catalog No.:BCC1880
CAS No.:940908-79-2
- PI 828
Catalog No.:BCC7494
CAS No.:942289-87-4
- 20-Dehydroeupatoriopicrin semiacetal
Catalog No.:BCN7370
CAS No.:94234-24-9
- Scutebarbatine I
Catalog No.:BCN1026
CAS No.:960302-84-5
- Cycloart-24-ene-1alpha,2alpha,3beta-triol
Catalog No.:BCN7983
CAS No.:942407-97-8
- VKGILS-NH2
Catalog No.:BCC3953
CAS No.:942413-05-0
- Nemoralisin
Catalog No.:BCN4488
CAS No.:942480-13-9
- PF-03814735
Catalog No.:BCC2184
CAS No.:942487-16-3
- Walsuronoid B
Catalog No.:BCN4489
CAS No.:942582-15-2
- 1,5,15-Tri-O-methylmorindol
Catalog No.:BCN4490
CAS No.:942609-65-6
- 5-Hydroxy-7,8,2',5'-tetramethoxyflavone 5-O-glucoside
Catalog No.:BCN1302
CAS No.:942626-75-7
- Dihydromicromelin B
Catalog No.:BCN4491
CAS No.:94285-06-0
- Acetyldihydromicromelin A
Catalog No.:BCN4492
CAS No.:94285-22-0
Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain.[Pubmed:27275127]
Saudi Pharm J. 2016 May;24(3):354-62.
This study is to establish a model of rat tibial osteocarcinoma pain, intrathecally inject specific ERK1/2 inhibitors SCH772984, observe the analgesic effect, and discuss the influence of ERK-P90RSK-Fos signal path in bone cancer pain. Forty female SD rats were randomly divided into 5 groups. Establish a bone cancer pain model after putting the intrathecal tube 5d and determine the rats' mechanical withdrawal threshold (MWT) after tube 5d; 40 SD rats with intrathecal tube back 5d were randomly divided into 5 groups. Sham Group receives no medication, the other four respectively receive 5% DMSO 10 mul, SCH 0.1, 1.0, 10 mug (SCH dissolved in 10 mul 5% DMSO) intrathecally. Determine the rats' mechanical withdrawal threshold (MWT) before and after giving medication 1, 3, 6, 9, 12, 15, 18, 24 h, and 2 min spontaneous paw withdrawal. Western blot and immuno-fluorescence determine the expression condition of spinal cord dorsal horn of p-ERK, p-p90RSK and Fos protein. Intrathecal injection of SCH772984 has analgesic effects on rats with bone cancer pain, and the effects enhance with increasing dose; intrathecal injection of SCH772984 10 mug could greatly reduce the expression of spinal dorsal horn Fos protein. Injecting walker 256 tumor cells into rats' tibia could cause behavior changes, such as idiopathic pain sensitivity and pain; the intrathecal tube almost has no effect on motor function of rats; ERK1/2 is involved in bone cancer pain, and intrathecal injection of ERK1/2 specific inhibitors SCH772984 10 mug may effectively relieve bone cancer pain.
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.[Pubmed:25142146]
Mol Cancer. 2014 Aug 20;13:194.
BACKGROUND: In melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no FDA-approved targeted therapies exist for BRAF-inhibitor-resistant BRAF(V600), NRAS mutant, or wild-type melanoma. METHODS: The 50% inhibitory concentration (IC50) of SCH772984, a novel inhibitor of ERK1/2, was determined in a panel of 50 melanoma cell lines. Effects on MAPK and AKT signaling by western blotting and cell cycle by flow cytometry were determined. RESULTS: Sensitivity fell into three groups: sensitive, 50% inhibitory concentration (IC50) < 1 muM; intermediately sensitive, IC50 1-2 muM; and resistant, >2 muM. Fifteen of 21 (71%) BRAF mutants, including 4 with innate vemurafenib resistance, were sensitive to SCH772984. All three (100%) BRAF/NRAS double mutants, 11 of 14 (78%) NRAS mutants and 5 of 7 (71%) wild-type melanomas were sensitive. Among BRAF(V600) mutants with in vitro acquired resistance to vemurafenib, those with MAPK pathway reactivation as the mechanism of resistance were sensitive to SCH772984. SCH772984 caused G1 arrest and induced apoptosis. CONCLUSIONS: Combining vemurafenib and SCH722984 in BRAF mutant melanoma was synergistic in a majority of cell lines and significantly delayed the onset of acquired resistance in long term in vitro assays. Therefore, SCH772984 may be clinically applicable as a treatment for non-BRAF mutant melanoma or in BRAF-mutant melanoma with innate or acquired resistance, alone or in combination with BRAF inhibitors.